Immunomodulatory therapies for acute pancreatitis

Table 1 Clinical trials of lexipafant in acute pancreatitis

Ref.	Study design	Severity of AP	No.	Interval	Dosage and administration	Major variables	Outcomes
Kingsnorth et al[74], 1995	Multi-center	Mix	83	< 48 h	60 mg/d, i.v., × 3 d	Organ failure	Positive
	double-blind					OFS
	RCT					IL6, IL8
McKay et al[75], 1997	Multi-center	APACHEII > 5,	50	< 72 h	100 mg/d, i.v., × 7 d	OFS	Positive
	double-blind	Glasgowscore ≥ 3, and				Systemic complications
	RCT	C-reactive protein ≥ 120 mg/L				Mortality
Johnson et al[76], 2001	Multi-center double-blind RCT	APACHEII > 6	290	< 72 h	100 mg/d, i.v., × 7 d	Systemic sepsis Pseudocysts New organ failure. Mortality	Positive in systemic sepsis and pseudocysts

AP: Acute pancreatitis; No.: Number of patients; Interval: Time interval between AP onset and the initiation of octreotide treatment; RCT: Randomized controlled trial; Mix: Mixture of APACHEII < 8 and APACHEII ≥ 8 acute pancreatitis patients; i.v.: Intravenous infusion; OFS: Organ failure score; IL: Interleukin; APACHE: Acute Physiology and Chronic Health Evaluation scale.